Intellectual functioning among case‐matched cohorts of children treated with proton or photon radiation for standard‐risk medulloblastoma. Issue 20 (13th July 2021)

• Record Type: Journal Article
• Authors: Eaton, Bree R.; Fong, Grace W.; Ingerski, Lisa M.; Pulsifer, Margaret B.; Goyal, Subir; Zhang, Chao; Weyman, Elizabeth A.; Esiashvili, Natia; Klosky, James L.; MacDonald, Tobey J.; Ebb, David H.; MacDonald, Shannon M.; Tarbell, Nancy J.; Yock, Torunn I.
• Is Part Of: Cancer. Volume 127:Issue 20(2021)
• Page Start: 3840
• Page End: 3846
• Publication Date: 2021-07-13
• Subjects: intelligence -- medulloblastoma -- neurocognitive -- pediatric -- photon -- proton -- radiation; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.33774
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: Proton therapy may reduce cognitive deficits after radiotherapy among brain tumor survivors, although current data are limited to retrospective comparisons between historical cohorts. The authors compared intelligence quotient scores within a case‐matched cohort of children with medulloblastoma treated with proton radiation (PRT) or photon radiation (XRT) over the same time period. METHODS: Among 88 consecutive patients with standard‐risk medulloblastoma treated with PRT or XRT at 2 institutions from 2000 to 2009, 50 were matched 1:1 (25 with PRT and 25 with XRT) according to age, gender, date of diagnosis, histology, radiation boost, and craniospinal irradiation dose. One‐way analyses of variance were performed to compare the Full‐Scale Intelligence Quotient (FSIQ) and associated index scores between the 2 cohorts. RESULTS: Neurocognitive data were available for 37 survivors (17 with PRT and 20 with XRT) from the matched cohort. The mean age was 8.5 years (SD, 4.14 years). The median follow‐up was 5.3 years (range, 1.0‐11.4 years) and 4.6 years (range, 1.1‐11.2 years) for the PRT and XRT cohorts, respectively ( P = .193). Patients treated with PRT had significantly higher mean FSIQ (99.6 vs 86.2; P = .021), verbal (105.2 vs 88.6; P = .010), and nonverbal scores (103.1 vs 88.9; P = .011) than the XRT‐treated cohort. Differences in processing speed (82.9 vs 77.2; P = .331) and working memory (97.0 vs 92.7; P = .388) were not statistically significant. CONCLUSIONS: Radiotherapy‐associated cognitive effects appear to be more attenuated after proton therapy. Comprehensive prospective studies are needed to appropriately evaluate the neurocognitive advantages of proton therapy. Abstract : In this case‐matched, multi‐institutional analysis, children with standard‐risk medulloblastoma have been treated with surgery, chemotherapy, and either contemporary proton or photon radiation over the same time period. After a median follow‐up of 5 years between radiation and neurocognitive assessment, children treated with proton therapy have demonstrated significantly higher Full‐Scale Intelligence Quotient, verbal, and nonverbal scores.